Cetera Investment Advisers
DNLI icon

Cetera Investment Advisers’s Denali Therapeutics DNLI Stock Holding History

Cetera Investment Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
11,569
+510
+5% +$10.5K ﹤0.01% 4159
2026
Q1 		$212K Buy
+11,059
New +$220K ﹤0.01% 4247
2025
Q2 		– Sell
-19,993
Closed -$272K – 4125
2025
Q1 		$272K Sell
19,993
-2,707
-12% -$51.9K ﹤0.01% 3346
2024
Q4 		$463K Buy
22,700
+403
+2% +$10.3K ﹤0.01% 2742
2024
Q3 		$650K Buy
22,297
+11,017
+98% +$273K ﹤0.01% 2440
2024
Q2 		$262K Buy
+11,280
New +$217K ﹤0.01% 3154

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's DNLI Position: Q2 2026 in Review

Cetera Investment Advisers increased its Denali Therapeutics (DNLI) stake by 4.6% in Q2 2026, buying an estimated $10.5K and bringing the position to 11,569 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #4159.

Cetera Investment Advisers first reported a position in DNLI in Q2 2024 and has held it in 6 quarters since. The position peaked at $650K in Q3 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Cetera Investment Advisers held 11,569 shares of Denali Therapeutics worth $298K as of Q2 2026.
  • Cetera Investment Advisers bought 510 Denali Therapeutics shares in Q2 2026, an estimated $10.5K.
  • Denali Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4159 holding.
  • Cetera Investment Advisers first reported a position in Denali Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Cetera Investment Advisers's Denali Therapeutics position peaked at $650K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.